Wu, Wei
Chen, Jiewen
Deng, Heran
Jin, Liang
He, Zhanghai
Rao, Nanyan
Nie, Yan
Yao, Yandan
Yang, Yaping
Su, Fengxi
Liu, Jieqiong
Article History
Received: 28 December 2020
Accepted: 16 July 2021
First Online: 27 July 2021
Declarations
:
: This trial has been approved and monitored by the Sun Yat-sen Memorial Hospital Institutional Review Board (protocol number 201608). This trial has been registered on 07/04/2016 and first posted on 18/04/2016 underExternalRef removedidentifier NCT02742051 (Name: A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer; URL:ExternalRef removed). Written informed consent is obtained from all patients prior to trial participation. All methods were conducted in accordance with the principles of Good Clinical Practice, and the provisions of the Declaration of Helsinki.
: Not applicable.
: The authors report no conflicts of interest.